Overview

Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of lymphocytic colitis.
Phase:
Phase 3
Details
Lead Sponsor:
Dr. Falk Pharma GmbH
Treatments:
Budesonide
Mesalamine